Chondroitin

What it does

Chondroitin sulfate is a sulfated glycosaminoglycan and a major structural component of cartilage, where its charged chains hold water and give the tissue compressive resistance. In laboratory studies it also inhibits some cartilage-degrading enzymes and inflammatory pathways. Supplemental chondroitin is extracted from animal cartilage (bovine, porcine, or shark), and purity and actual content vary widely between pharmaceutical-grade preparations and ordinary supplements, which complicates both research and buying.

What the research says

• Reduces knee osteoarthritis pain modestly in the short term

  Evidence: moderate. A Cochrane review of 43 trials and 9,110 participants (Singh et al., 2015, CD005614) found chondroitin slightly better than placebo for pain in studies under 6 months (about 8 points on a 0 to 100 scale), with most trials at low quality. In the CONCEPT trial (Reginster et al., Ann Rheum Dis 2017;76:1537-1543), pharmaceutical-grade chondroitin sulfate 800 mg/day beat placebo and matched celecoxib 200 mg/day over 6 months in 604 patients, though the trial was industry-funded. Against that, chondroitin alone was no better than placebo in GAIT (Clegg et al., N Engl J Med 2006).

• May slightly slow joint space narrowing and cartilage loss

  Evidence: emerging. The Cochrane review found chondroitin slightly slowed joint space narrowing on X-ray versus placebo. In the LEGS trial (Fransen et al., Ann Rheum Dis 2015), the significant 2-year structural benefit (0.10 mm less narrowing) belonged to the glucosamine-chondroitin combination, not chondroitin alone, and the 2-year MOSAIC MRI study (Martel-Pelletier et al., Arthritis Res Ther 2016) found less cartilage volume loss with chondroitin than celecoxib in some subregions in exploratory analyses. The BMJ network meta-analysis (Wandel et al., 2010) found no effect on joint space narrowing. Structure modification remains unproven.

• Taken with glucosamine, is associated with lower mortality in observational cohorts

  Evidence: emerging. In an NHANES cohort of 16,686 US adults, people taking glucosamine/chondroitin for a year or more had multivariable-adjusted hazard ratios of 0.73 for all-cause and 0.42 for cardiovascular mortality over a median 107 months (King and Xiang, J Am Board Fam Med 2020;33:842-847). This is observational, combination-only data with strong potential for healthy-user bias; it cannot be credited to chondroitin specifically and no trial has tested it.

The average effect across meta-analyses is small and real-looking but fragile: the Cochrane review found a modest short-term pain benefit from mostly low-quality trials, and the effect shrank or vanished in higher-quality sensitivity analyses and in the BMJ network meta-analysis. Its best single trial, CONCEPT, was well designed but industry-funded and used a pharmaceutical-grade product that most supplements do not match. Chondroitin alone failed its GAIT arm. Guidelines split exactly as they do for glucosamine: ESCEO (2019) recommends prescription chondroitin sulfate as step-1 background therapy, while the American College of Rheumatology (2019) strongly recommends against it for knee and hip OA and only conditionally supports it for hand OA. Excellent safety keeps it at C+ rather than lower; thin, quality-dependent efficacy keeps it from going higher.

Is it worth it?

Evidence (C+) sits below the leaderboard floor, so the worth-it grade is capped at C+ however inexpensive it is. About $18 a month at a common dose. Derived from the October 2026 worth-it model.

Frequently asked questions